Beating the biotech blues
This year, small- and mid-cap biotech stocks are experiencing their worst period of relative underperformance on record. Portfolio Manager Andy Acker explains the reason for the pullback and why he’s optimistic the industry can make a strong recovery.
- While the S&P 500 Index and healthcare sector have experienced double-digit gains in 2021, small- and mid-size biotech stocks have fallen into a prolonged bear market.
- We believe recent headwinds are largely transitory and don’t outweigh the industry’s long-term growth potential.
- In the meantime, the pullback has resulted in lower valuations. In our view, that could set up biotech for a big rebound.
So far this year, the S&P 500® health care sector, like the broader S&P 500® Index, has enjoyed double-digit returns. But within health care, biotechnology – in particular, small- and mid-cap stocks – have experienced a notably less positive run.
For the year through August 26, the SPDR S&P Biotech ETF (XBI) has fallen 8.6%, compared with a gain of roughly 20% for both the health care sector and the S&P 500.1 (The XBI serves as a proxy benchmark for biotech’s small- and mid-size components.)2 Looking at performance since the industry’s record high on February 8, things are downright gloomy: the XBI has retreated just over 26%, while the health care sector has climbed 17.3% and the S&P 500, 15.1%.3
Exhibit 1: biotech bear market
Small- and mid-cap biotechnology stocks have dramatically underperformed both the S&P 500 Index and the health care sector since February.
Source: Bloomberg. Data from 8 February 2021 to 26 August 2021. Indices rebased to 100 as of 8 February 2021.
The XBI’s underperformance relative to the equity market and the health care sector overall is the widest it has been since the ETF’s inception in 2006. The pullback – officially a bear market (defined as a loss of 20% or more) — is also on track to be one of the longest in history, so far lasting 139 trading days, or nearly three times the length of the XBI’s average bear market.4
What’s behind the underperformance
Biotech’s fall has been even more jarring when compared with the experience of 2020 – when investors rewarded companies developing treatments and vaccines for COVID-19 and enthusiasm for still-unproven medicines seemed to have no limit.
But sentiment toward the industry made a sharp U-turn in early 2021. For one, investors began rotating out of long-duration growth stocks such as biotech and into areas levered to an economic recovery. Market participants also demonstrated a preference for high-quality, large-capitalization stocks over smaller, less liquid peers. In addition, a decision by the U.S. Federal Trade Commission to scrutinize recent mergers and acquisitions (M&A) in pharma dampened appetite for new deals, while worries about drug pricing reform resurfaced as Democrats in Congress looked for ways to fund ambitious spending bills. Finally, the commissioner of the Food and Drug Administration (FDA) departed, creating a vacuum in leadership as the agency faced an influx of COVID-19 drug applications, resulting in delayed reviews and surprising regulatory decisions.
Big losses, big rebounds
Given the inherent risk and long timelines for drug development, biotech is no stranger to volatility. But thankfully, big drawdowns can also be followed by big rebounds. In 2015-2016, the XBI underperformed the S&P 500 by 35%, the second-largest return gap on record (prompted, in part, by a tweet from then-U.S. presidential candidate Hillary Clinton about “price gouging” in biotech drugs).5 From that bottom in 2016 to biotech’s high this year, the XBI delivered returns of over 280% (see Exhibit 2).
Exhibit 2: biotech bounce-back
Following a major sell-off in 2015-2016, small- and mid-size biotech stocks went on to deliver sizable gains, hitting a record high in February 2021.
Source: Bloomberg. Data reflect total returns for the SPDR S&P Biotech ETF (XBI). Decline period is from 17 July 2015 to 11 February 2016. Gains are for the period from 11 February 2016 to 08 February 2021.
Our take on biotech now
We cannot predict when the current biotech rout will end. But in our view, the fundamentals driving the industry’s attractive growth opportunities have remained intact. Small- and mid-cap biotech companies are pioneering some of the most exciting advances in medical research, such as gene therapies, liquid biopsies, precision oncology and engineered antibodies. Many of these medicines have the potential to revolutionize the standard of care for patients, dramatically improving survival rates and quality of life.
In June, for example, Intellia Therapeutics delivered the first positive clinical trial data for in-vivo gene editing, a process by which a specific point in the human genome is edited from within the body. Intellia was able to knock down a harmful protein for patients with a fatal hereditary disease by an average of 87% — with just a single infusion. While the data are still early, the outcome is remarkable and suggests gene editing therapies could have enormous potential.
Meanwhile, biotech stocks now trade well below the long-term average (see Exhibit 3) due to the challenges described earlier. But in our view, these headwinds should pass. For one, the eventual appointment of an FDA commissioner should lead to greater regulatory consistency. At the same time, progress on infrastructure bills and other spending measures in the U.S. should help reduce uncertainty about drug pricing. On that point, we’d note the Biden administration has demonstrated consistent support for biomedical research, and we believe this will factor into any efforts at reform. This is particularly true in the wake of the industry’s enormous contributions to fighting the COVID-19 pandemic and as China ramps up investment in its own biotech industry.
Exhibit 3: Biotech valuations drop
The forward price-to-earnings (P/E) ratio for the typical biotech stock sits well below the long-term average for the sector, as well as the S&P 500.
Source: Bloomberg, data are from 30 September 1992 through 31 July 2021. Data are quarterly except for July 2021, and based on forward, one-year earnings estimates. Price-to-Earnings (P/E) Ratio measures share price compared to earnings per share for a stock or stocks in a portfolio.
“Volatility is the price of admission” when investing in biotech, but we remain optimistic about the long-term view. In fact, after large drawdowns, the returns can be significant. In August, Pfizer announced it would acquire Trillium Therapeutics, a Canadian biotech developing blood cancer drugs, for nearly U.S. $2.3 billion, a more than 200% premium to Trillium’s prior-day closing price.6 Should we see more M&A deals such as this, biotech’s blues could well come to an end.
1Bloomberg, as of 26 August 2021. Health care returns are for the S&P 500 Health Care Sector.
2The SPDR S&P Biotech ETF (XBI) corresponds generally to the total return performance of an index derived from the biotechnology segment of a U.S. total market composite index.
3Bloomberg, data are from 8 February 2021 to 26 August 2021.
4Goldman Sachs Global Investment Research, FactSet, Bloomberg. Data as of 20 August 2021 and 26 August 2021.
5Goldman Sachs Global Investment Research, FactSet. Data as of 20 August 2021.
6Bloomberg, as of 20 August 2021.
The S&P 500 Health Care comprises those companies included in the S&P 500 that are classified as members of the GICS® health care sector.
The health care industries are subject to government regulation and reimbursement rates, as well as government approval of products and services, which could have a significant effect on price and availability, and can be significantly affected by rapid obsolescence and patent expirations.
Please read the following important information regarding funds related to this article.
- Shares/Units can lose value rapidly, and typically involve higher risks than bonds or money market instruments. The value of your investment may fall as a result.
- Shares of small and mid-size companies can be more volatile than shares of larger companies, and at times it may be difficult to value or to sell shares at desired times and prices, increasing the risk of losses.
- If a Fund has a high exposure to a particular country or geographical region it carries a higher level of risk than a Fund which is more broadly diversified.
- The Fund is focused towards particular industries or investment themes and may be heavily impacted by factors such as changes in government regulation, increased price competition, technological advancements and other adverse events.
- The Fund may use derivatives towards the aim of achieving its investment objective. This can result in 'leverage', which can magnify an investment outcome and gains or losses to the Fund may be greater than the cost of the derivative. Derivatives also introduce other risks, in particular, that a derivative counterparty may not meet its contractual obligations.
- If the Fund holds assets in currencies other than the base currency of the Fund or you invest in a share/unit class of a different currency to the Fund (unless 'hedged'), the value of your investment may be impacted by changes in exchange rates.
- When the Fund, or a hedged share/unit class, seeks to mitigate exchange rate movements of a currency relative to the base currency, the hedging strategy itself may create a positive or negative impact to the value of the Fund due to differences in short-term interest rates between the currencies.
- Securities within the Fund could become hard to value or to sell at a desired time and price, especially in extreme market conditions when asset prices may be falling, increasing the risk of investment losses.
- The Fund may incur a higher level of transaction costs as a result of investing in less actively traded or less developed markets compared to a fund that invests in more active/developed markets. These transaction costs are in addition to the Fund's Ongoing Charges.
- The Fund could lose money if a counterparty with which the Fund trades becomes unwilling or unable to meet its obligations, or as a result of failure or delay in operational processes or the failure of a third party provider.